Sector News

UK drugmakers back in spotlight as bidders free to return

November 24, 2014
Life sciences
Two of the UK’s biggest health care companies, AstraZeneca and Smith & Nephew, will be pushed into the spotlight again this week as bidding restrictions on their former suitors expire.
 
After a six-month cooling off period, US drugmaker Pfizer will be able to approach AstraZeneca again, while the American orthopaedic company Stryker will also be allowed to return for hip and knee replacement maker Smith & Nephew.
 
Stryker is understood to be still keen but unlikely to return immediately after the takeover deadline ends on Friday. It is expected to return next year.
 
Stryker is under pressure to do a deal as its orthopaedic rivals, Zimmer, Biomet and Johnson & Johnson have already struck their own blockbuster deals.
 
However, sources have called the Pfizer-AstraZeneca situation “dead” and said the US drugmaker is now focused on other opportunities. Pfizer was said to have turned its attentions to rival US drugmaker Actavis, but Actavis bulked up with its $66bn acquisition of Allergan. The Swiss biotech company Actelion has also been on its radar.
 
Meanwhile, AstraZeneca’s share price has risen on the back of a boost in its pipeline, making it unlikely that Pfizer would be able to afford the group, particularly now the tax benefits of a deal have been complicated by new US Treasury rules.
 
Takeover Panel rules require bidders to walk away for six months after a failed bid, but few return. The last occasion was in 2001 when French industrial group Lafarge returned for UK cement maker Blue Circle.
 
By Ashley Armstrong
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).